Vivek Subbiah, MD
LightNews LightNews
banner
viveksubbiah.bsky.social
Vivek Subbiah, MD
@viveksubbiah.bsky.social
2.9K followers 290 following 48 posts
Early Phase Drug Development; Oncologist; Precision Medicine; Phase 1 trials; AI & Precision Oncology; Clinical trials. Posts=My own
Posts Replies Media Videos
Reposted by Vivek Subbiah, MD
oncodaily.bsky.social
Thrilled to Share My Editorial on the ROME Trial - Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Vivek Subbiah: Thrilled to Share My Editorial on the ROME Trial - OncoDaily
Vivek Subbiah: Thrilled to Share My Editorial on the ROME Trial / Agnese Fabbri, Alberto Zambelli, Andrea Botticelli, Andrea DeCensi, Annamaria Pessino, Bruna
oncodaily.com
November 13, 2025 at 9:44 PM
Reposted by Vivek Subbiah, MD
oncodaily.bsky.social
ONE of the Most Impactful Meetings in Rare Cancer Research - Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Vivek Subbiah: ONE of the Most Impactful Meetings in Rare Cancer Research - OncoDaily
Vivek Subbiah: ONE of the Most Impactful Meetings in Rare Cancer Research / cancer, OncoDaily, Oncology, Razelle Kurzrock, Target Cancer Foundation, Think
oncodaily.com
November 2, 2025 at 9:42 PM
Reposted by Vivek Subbiah, MD
hannahrabrams.bsky.social
2. Need structured approaches for how to evaluate even when an ultra-specific histology driven approach isn't feasible, as @viveksubbiah.bsky.social outlines for rare cancers here: ascopubs.org/doi/10.1200/...
Imperative of Comprehensive Molecular Profiling as Standard of Care for Patients With Rare Cancers | JCO Oncology Practice
ascopubs.org
October 28, 2025 at 1:04 AM
Reposted by Vivek Subbiah, MD
aacrjournals.bsky.social
Read the Cancer Discovery Piece: Rethinking Cancer Drug Development through Tumor-Agnostic Precision Medicine by @viveksubbiah.bsky.social doi.org/10.1158/2159...
i-mei.bsky.social I-Mei @i-mei.bsky.social · Oct 20
Great #ESMO25 talk by @viveksubbiah.bsky.social on targeting molecular drivers of cancer in a tissue-agnostic manner: for more of his thoughts, check out his @aacrjournals.bsky.social Cancer Discovery piece (online as of October 17) here:
October 20, 2025 at 1:37 PM
Reposted by Vivek Subbiah, MD
oncodaily.bsky.social
ESMO 2025 - Catalyzing Novel Collaborations for Global Impact in Oncology - Vivek Subbiah

@viveksubbiah.bsky.social @myesmo.bsky.social

oncodaily.com/voices/esmo-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO25
Vivek Subbiah: ESMO 2025 - Catalyzing Novel Collaborations for Global Impact in Oncology - OncoDaily
Vivek Subbiah: ESMO 2025 - Catalyzing Novel Collaborations for Global Impact in Oncology / cancer, ESMO, ESMO 2025, OncoDaily, Oncology, Vivek Subbiah
oncodaily.com
October 11, 2025 at 6:58 PM
Reposted by Vivek Subbiah, MD
oncodaily.bsky.social
Honored to Present at ESMO Annual Meeting Young Oncologists Clinical Case Discussions - Vivek Subbiah

@viveksubbiah.bsky.social @myesmo.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Vivek Subbiah: Honored to Present at ESMO Annual Meeting Young Oncologists Clinical Case Discussions - OncoDaily
Vivek Subbiah: Honored to Present at ESMO Annual Meeting Young Oncologists Clinical Case Discussions / cancer, ESMO Annual Meeting, ESMO25, Maximilian Kloft,
oncodaily.com
October 12, 2025 at 10:28 PM
Reposted by Vivek Subbiah, MD
oncodaily.bsky.social
Precision Oncology and Modernizing Evidence Standards - Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Vivek Subbiah: Precision Oncology and Modernizing Evidence Standards - OncoDaily
Vivek Subbiah: Precision Oncology and Modernizing Evidence Standards / cancer, OncoDaily, Oncology, Razelle Kurzrock, Vivek Subbiah
oncodaily.com
October 13, 2025 at 7:03 PM
Reposted by Vivek Subbiah, MD
oncodaily.bsky.social
ESMO Presidential Dinner is Kicking Off in Berlin - Vivek Subbiah

@viveksubbiah.bsky.social @myesmo.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025
Vivek Subbiah: ESMO Presidential Dinner is Kicking Off in Berlin - OncoDaily
Vivek Subbiah: ESMO Presidential Dinner is Kicking Off in Berlin / cancer, ESMO, ESMO 2025, ESMO 2025 Congress, ESMO Presidential Dinner, ESMO2025, ESMO25,
oncodaily.com
October 20, 2025 at 10:02 PM
Reposted by Vivek Subbiah, MD
oncodaily.bsky.social
Rethinking Cancer Drug Development Through Tumor-Agnostic Precision Medicine - Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025
Vivek Subbiah: Rethinking Cancer Drug Development Through Tumor-Agnostic Precision Medicine - OncoDaily
Vivek Subbiah: Rethinking Cancer Drug Development Through Tumor-Agnostic Precision Medicine / cancer, ESMO, ESMO 2025, ESMO 2025 Congress, ESMO2025, ESMO25,
oncodaily.com
October 18, 2025 at 2:48 PM
Reposted by Vivek Subbiah, MD
i-mei.bsky.social
Great #ESMO25 talk by @viveksubbiah.bsky.social on targeting molecular drivers of cancer in a tissue-agnostic manner: for more of his thoughts, check out his @aacrjournals.bsky.social Cancer Discovery piece (online as of October 17) here:
October 20, 2025 at 6:37 AM
Reposted by Vivek Subbiah, MD
oncodaily.bsky.social
Smarter Trial Designs: How Project Optimus is Changing Early-Phase Cancer Research - Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Vivek Subbiah: Smarter Trial Designs - How Project Optimus is Changing Early-Phase Cancer Research - OncoDaily
Vivek Subbiah: Smarter Trial Designs - How Project Optimus is Changing Early-Phase Cancer Research / American Society of Clinical Oncology, ASCO, cancer,
oncodaily.com
October 7, 2025 at 9:31 PM
Reposted by Vivek Subbiah, MD
jiajennyliu.bsky.social
D-7 until #ESMO25! 👋🇩🇪

Excited to be part of first ever tumor-agnostic scientific track with @viveksubbiah.bsky.social @JulianaRBeale #NiamhColeman

Don’t miss these educational sessions! ⬇️ @myesmo.bsky.social
October 10, 2025 at 8:22 AM
Reposted by Vivek Subbiah, MD
oncodaily.bsky.social
Impact of FDA Project Optimus Guidance on Early-Phase Trial Design - Vivek Subbiah

@viveksubbiah.bsky.social @fda.gov

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Vivek Subbiah: Impact of FDA Project Optimus Guidance on Early-Phase Trial Design - OncoDaily
Vivek Subbiah: Impact of FDA Project Optimus Guidance on Early-Phase Trial Design / cancer, David Spigel, Deepak Bhamidipati, Gerald Falchook, Howard Burris,
oncodaily.com
September 29, 2025 at 9:33 PM
Reposted by Vivek Subbiah, MD
oncodaily.bsky.social
Honored to Join Global Colleagues and Deliver the Message at the UN for The Last Mile Series - Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Vivek Subbiah: Honored to Join Global Colleagues and Deliver the Message at the UN for The Last Mile Series - OncoDaily
Vivek Subbiah: Honored to Join Global Colleagues and Deliver the Message at the UN for The Last Mile Series / cancer, International Cancer Patient Coalition,
oncodaily.com
September 24, 2025 at 3:03 PM
viveksubbiah.bsky.social
⭐️When AI rejects your grant proposal: algorithms are helping to make funding decisions
A foundation using an AI tool to screen grant applications says it makes the peer-review process more efficient, but other researchers say it’s a breakdown in trust
www.nature.com/articles/d41...
When AI rejects your grant proposal: algorithms are helping to make funding decisions
A Spanish foundation using an artificial-intelligence tool to screen grant applications says it makes the peer-review process more efficient, but other researchers say it’s a breakdown in trust.
www.nature.com
September 28, 2025 at 6:39 PM
Reposted by Vivek Subbiah, MD
rielymd.bsky.social
Appropriately critical commentary on cochrane reviews as the apply to matched targeted therapy by @viveksubbiah.bsky.social Journal of Clinical Oncology ascopubs.org/doi/full/10....
Precision Oncology and Modernizing Evidence Standards: A Critical Commentary on the Cochrane Review
ascopubs.org
September 22, 2025 at 9:17 PM
Reposted by Vivek Subbiah, MD
smohahm.bsky.social
PFS benefit noted with adagrasib
August 12, 2025 at 2:40 AM
Reposted by Vivek Subbiah, MD
oncodaily.bsky.social
10 Must-Read Posts in Immuno-Oncology This Week

@viveksubbiah.bsky.social @jiajennyliu.bsky.social @gerryhanna.bsky.social @drjnaidoo.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #IO #ImmuneOncology
10 Must-Read Posts in Immuno-Oncology This Week - OncoDaily
10 Must-Read Posts in Immuno-Oncology This Week / Alex Menzies, Alexander Van Akkooi, AndrewFurness, cancer, chemoimmunotherapy, Christian Blank, David
oncodaily.com
August 24, 2025 at 9:58 PM
Reposted by Vivek Subbiah, MD
oncodaily.bsky.social
Nature Medicine Study on Molecular Profiling in Meningioma - @viveksubbiah.bsky.social

oncodaily.com/science/vive...

#OncoDaily #Oncology #Cancer #Health #Medicine
Vivek Subbiah: Nature Medicine Study on Molecular Profiling in Meningioma - OncoDaily
Vivek Subbiah: Nature Medicine Study on Molecular Profiling in Meningioma / Alexander P. Landry, Andrew Ajisebutu, cancer, Chloe Gui, Farshad Nassiri, Gelareh
oncodaily.com
September 4, 2025 at 1:31 AM
Reposted by Vivek Subbiah, MD
oncodaily.bsky.social
Rare Cancers Deserve Breakthroughs Too - Vivek Subbiah

@viveksubbiah.bsky.social @conquercancer.bsky.social

oncodaily.com/blog/rare-ca...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Vivek Subbiah: Rare Cancers Deserve Breakthroughs Too - OncoDaily
Vivek Subbiah: Rare Cancers Deserve Breakthroughs Too / American Society of Clinical Oncology, ASCO, cancer, Conquer Cancer, Conquer Cancer the ASCO
oncodaily.com
September 13, 2025 at 2:15 PM
Reposted by Vivek Subbiah, MD
oncodaily.bsky.social
Top Articles Suggested by Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Top Articles Suggested by Vivek Subbiah - OncoDaily
Top Articles Suggested by Vivek Subbiah / cancer, Nature, NEJM, OncoDaily, Oncology, Vivek Subbiah
oncodaily.com
September 14, 2025 at 1:20 PM
Reposted by Vivek Subbiah, MD
jamaoncology.com
🔊 Listen to Jiyoung Ahn, PhD, of New York University, discuss with @viveksubbiah.bsky.social, MD, about whether the oral bacterial and fungal microbiome is associated with the development of pancreatic #cancer.

Listen now: ja.ma/41Vzuh9
Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer
Interview with Jiyoung Ahn, PhD, author of Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. Hosted by Vivek Subbiah, MD.
ja.ma
September 18, 2025 at 4:15 PM
Reposted by Vivek Subbiah, MD
oncodaily.bsky.social
Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center - Vivek Subbiah

@viveksubbiah.bsky.social @fredhutch.org

oncodaily.com/career/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Vivek Subbiah: Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center - OncoDaily
Vivek Subbiah: Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center / cancer, Fred Hutch Cancer Center, OncoDaily,
oncodaily.com
September 21, 2025 at 6:17 PM
Reposted by Vivek Subbiah, MD
oncodaily.bsky.social
Top 5 Articles of the Week Suggested by Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Top 5 Articles of the Week Suggested by Vivek Subbiah - OncoDaily
Top 5 Articles of the Week Suggested by Vivek Subbiah / cancer, Cancer Discovery, Nature, OncoDaily, Oncology, Sarah Cannon Research Institute, Vivek Subbiah
oncodaily.com
September 21, 2025 at 6:18 PM
viveksubbiah.bsky.social
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial - The Lancet www.thelancet.com/journals/lan...
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
Adagrasib demonstrated a statistically significant improvement in progression-free survival over docetaxel in patients with previously treated KRASG12C-mutated NSCLC, without new safety signals.
www.thelancet.com
August 11, 2025 at 11:51 AM